Everest Medicines Strikes Potential Up-to-$1.1-Billion Out-Licensing Deal for Core Renal Drug Candidate

Everest Medicines (HKEX:1952.HK) announced on the evening of June 2, 2026 an exclusive licensing pact with U.S.-based rare disease specialist Travere Therapeutics (NASDAQ:TVTX), granting the U.S. firm global development and commercial rights to civorebrutinib(EVER001), its self-discovered next-generation reversible covalent BTK inhibitor, excluding territories covering Greater China and certain Southeast Asian nations.

Per contractual terms, Everest Medicines is entitled to an upfront payment of $112.5 million, alongside up to $1.03 billion in cumulative milestone payments tied to development, regulatory approval and commercial rollout across a maximum of five approved indications. The biotech will additionally collect tiered mid-to-high single-digit up to double-digit percentage royalties calculated on annual net product sales, putting the deal’s aggregate potential consideration above $1.1 billion.

As a core signaling node governing B-cell receptor pathways, Bruton’s tyrosine kinase (BTK) modulates B lymphocyte activation, proliferation and autoantibody generation, marking a pivotal therapeutic target for immune-mediated kidney ailments. Traditional irreversible covalent BTK inhibitors trigger sustained target suppression linked to severe adverse effects and elevated safety risks; meanwhile, standard-of-care clinical treatments including corticosteroids and conventional immunosuppressants are plagued by low disease remission rates, frequent relapse and marked nephrotoxicity. To date, no pharmaceutical therapy has secured global regulatory approval specifically for primary membranous nephropathy (pMN), leaving substantial unmet clinical demand unaddressed worldwide.

Originally discovered by Evopoint Biosciences, EVER001 was licensed in September 2021 by Everest Medicines for global development and commercialization across all renal disease indications. Its proprietary reversible covalent binding design delivers potent target activity paired with superior molecular selectivity, effectively mitigating safety hazards stemming from prolonged uninterrupted BTK inhibition.

The drug boasts broad-spectrum multi-indication development prospects spanning pMN, IgA nephropathy, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and lupus nephritis. Data from its ongoing Phase 1b/2a clinical trial for pMN conducted in mainland China has yielded standout efficacy and safety readouts: anti-PLA2R autoantibody concentrations dropped by nearly 93% in both low-dose and high-dose cohorts by Week 24. Patients on the low-dose arm registered a 78% average reduction in proteinuria at Week 36, with sustained therapeutic benefits persisting through Week 52, translating to clinical remission rates ranging from 76.9% to 88.2% alongside stable renal function and no severe treatment-emergent adverse events (TEAEs) across trial participants.

Encouraging clinical outcomes validate EVER001’s therapeutic promise for proteinuric autoimmune nephritis, paving the path for upcoming clinical trials targeting other immune-driven renal pathologies including MCD and FSGS, with potential future expansion into lupus nephritis treatment.

The landmark out-licensing transaction encapsulates the core corporate strategy Everest Medicines has adhered to since inception.

The Hong Kong-listed biotech has long anchored its growth on a dual operational framework combining in-licensed asset introduction and internal innovative drug development, diverging from peer biotech players that concentrate resources on a single technical platform. The company centers its pipeline build around clinical unmet needs to source differentiated innovative candidates and unlock full commercial value via end-to-end capabilities covering clinical development, regulatory authorization and market launch.

NEFECON®, also known as budesonide controlled-release capsules, serves as the poster child for this dual-business model. Secured via an in-licensing agreement with Calliditas for Greater China and Singapore rights back in 2019, the product was successfully rolled out across Asian markets by Everest Medicines and became China’s first disease-modifying therapy approved for IgA nephropathy. Notching annual sales exceeding RMB1.4 billion in 2025, NEFECON® has not only proven its commercial viability but also enabled Everest Medicines to build a full-stack nephrology commercial ecosystem spanning medical affairs, market access and field sales teams.

Building on its successful in-licensing track record, Everest Medicines has evolved its business blueprint from importing global novel therapeutics toward co-developing breakthrough drugs for worldwide markets, with the EVER001 out-licensing deal embodying this strategic shift.

Beyond EVER001, the firm has steadily bulked up its renal-focused pipeline portfolio: it previously obtained development rights to MT-1013 from Mediar Therapeutics to advance therapies targeting renal fibrosis. Its overall therapeutic footprint now stretches across autoimmune disorders, ophthalmology, critical care and CKM (cardiovascular, kidney and metabolic) diseases.

On the counterparty side, Travere Therapeutics ranks among the world’s few biotech firms with a long-standing exclusive focus on renal disease drug development. Unlike large-cap pharma groups with sprawling cross-therapeutic-area pipelines, Travere leverages decades of accumulated expertise in nephrology clinical trial design, regulatory negotiation and patient support infrastructure. Its flagship asset FILSPARI® (sparsentan) has secured regulatory nods for IgA nephropathy and FSGS indications. As FILSPARI® advances into full commercialization, the U.S. biotech has actively hunted new pipeline additions to reinforce its autoimmune nephritis portfolio, and EVER001 fills a critical gap within its product lineup by adding a BTK-targeted therapeutic modality.

Beneath the high-value licensing deal lies an emerging industry paradigm sweeping China’s biotech sector: domestic drug developers source global innovative molecules via business development (BD) partnerships, complete clinical validation and value elevation on home soil, then partner with international pharmaceutical players to commercialize assets globally.

Autoimmune nephropathy has emerged as a high-growth frontier for global novel drug R&D. Internal research from Everest Medicines pegs China’s IgA nephropathy patient pool above 5 million, with roughly 100,000 newly diagnosed cases annually, alongside around 2 million patients living with primary membranous nephropathy nationwide. Despite the vast patient population, treatment regimens for most such renal illnesses still rely heavily on corticosteroids and generic immunosuppressants constrained by suboptimal efficacy and safety profiles, sustaining persistent unmet medical demand.

Strong clinical needs have fueled a robust R&D boom across the nephrology space, with novel therapies targeting complement cascades, B-cell regulation, BAFF/APRIL and endothelin pathways hitting preclinical and clinical pipelines in recent years. Industry competition has shifted from standalone product rivalry toward differentiated mechanism-driven pipeline construction. Novartis has assembled a diversified nephrology portfolio anchored by Iptacopan, an oral complement factor B inhibitor, and Atrasentan, an endothelin receptor antagonist; Vertex bolstered its autoimmune kidney disease footprint with a $4.9 billion takeover of Alpine Immune Sciences, whose lead candidate povetacicept is a dual BAFF/APRIL inhibitor. Leading domestic Chinese developers meanwhile advance proprietary renal candidates across disparate technical routes: RemeGen’s telitacicept, a TACI-Fc fusion protein; Hengrui Pharma’s HR19042, an innovative gut-targeted delayed-release budesonide formulation; Mabworks’ MIL62(Bejiexin), a third-generation anti-CD20 monoclonal antibody; plus EVER001 featured in the latest cross-border licensing transaction, a novel BTK inhibitor.

Among all novel pharmacological mechanisms under development for nephritis, BTK inhibition stands out as a high-potential modality. Pharmacologically, BTK pathway overactivation drives aberrant B-cell function, a core pathogenic driver of autoimmune renal damage. While BTK-targeted medicines have achieved widespread clinical success for hematological malignancies, safety limitations associated with traditional irreversible BTK blockers have slowed their advancement into nephrology indications, leaving the field in early exploratory stages.

EVER001’s reversible covalent chemistry and refined selectivity profile resolve immune-related toxicities triggered by permanent BTK suppression, while its oral administration route boosts patient treatment adherence, carving out clear differentiation from monoclonal antibodies, hormone regimens and complement inhibitor therapeutics.

With ongoing clinical progression and incremental data readouts slated for EVER001, the landmark licensing agreement transcends a simple Chinese biotech outbound product licensing deal, evolving into a pivotal real-world case study to test the commercial and clinical viability of BTK inhibitors across the global nephropathy treatment landscape.